Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115121314> ?p ?o ?g. }
- W3115121314 endingPage "26" @default.
- W3115121314 startingPage "1" @default.
- W3115121314 abstract "Current hypertension guidelines fail to provide a recommendation on when-to-treat, thus disregarding relevant circadian rhythms that regulate blood pressure (BP) level and 24 h patterning and medication pharmacokinetics and pharmacodynamics. The ideal purpose of ingestion-time (chronopharmacology, i.e. biological rhythm-dependent effects on the kinetics and dynamics of medications, and chronotherapy, i.e. the timing of pharmaceutical and other treatments to optimize efficacy and safety) trials should be to explore the potential impact of endogenous circadian rhythms on the effects of medications. Such investigations and outcome trials mandate adherence to the basic standards of human chronobiology research. In-depth review of the more than 150 human hypertension pharmacology and therapeutic trials published since 1974 that address the differential impact of upon-waking/morning versus at-bedtime/evening schedule of treatment reveals diverse protocols of sometimes suboptimal or defective design and conduct. Many have been time-of-day, i.e. morning versus evening, rather than circadian-time-based, and some relied on wake-time office BP rather than around-the-clock ambulatory BP measurements (ABPM). Additionally, most past studies have been of too small sample size and thus statistically underpowered. As of yet, there has been no consensual agreement on the proper design, methods and conduct of such trials. This Position Statement recommends ingestion-time hypertension trials to follow minimum guidelines: (i) Recruitment of participants should be restricted to hypertensive individuals diagnosed according to ABPM diagnostic thresholds and of a comparable activity/sleep routine. (ii) Tested treatment-times should be selected according to internal biological time, expressed by the awakening and bed times of the sleep/wake cycle. (iii) ABPM should be the primary or sole method of BP assessment. (iv) The minimum-required features for analysis of the ABPM-determined 24 h BP pattern ought to be the asleep (not nighttime) BP mean and sleep-time relative BP decline, calculated in reference to the activity/rest cycle per individual. (v) ABPM-obtained BP means should be derived by the so-called adjusted calculation procedure, not by inaccurate arithmetic averages. (vi) ABPM should be performed with validated and calibrated devices at least hourly throughout two or more consecutive 24 h periods (48 h in total) to achieve the highest reproducibility of mean wake-time, sleep-time and 48 h BP values plus the reliable classification of dipping status. (vii) Calculation of minimum required sample size in adherence with proper statistical methods must be provided. (viii) Hypertension chronopharmacology and chronotherapy trials should preferably be randomized double-blind, randomized open-label with blinded-endpoint, or crossover in design, the latter with sufficient washout period between tested treatment-time regimens." @default.
- W3115121314 created "2021-01-05" @default.
- W3115121314 creator A5001920865 @default.
- W3115121314 creator A5010180960 @default.
- W3115121314 creator A5014964771 @default.
- W3115121314 creator A5016801438 @default.
- W3115121314 creator A5016887531 @default.
- W3115121314 creator A5018699045 @default.
- W3115121314 creator A5021565751 @default.
- W3115121314 creator A5023887337 @default.
- W3115121314 creator A5028127728 @default.
- W3115121314 creator A5028802207 @default.
- W3115121314 creator A5036071355 @default.
- W3115121314 creator A5038346349 @default.
- W3115121314 creator A5043929987 @default.
- W3115121314 creator A5049166098 @default.
- W3115121314 creator A5049479060 @default.
- W3115121314 creator A5049934203 @default.
- W3115121314 creator A5053151546 @default.
- W3115121314 creator A5066259109 @default.
- W3115121314 creator A5070275934 @default.
- W3115121314 creator A5083433627 @default.
- W3115121314 creator A5085671543 @default.
- W3115121314 creator A5091665654 @default.
- W3115121314 date "2020-12-20" @default.
- W3115121314 modified "2023-10-14" @default.
- W3115121314 title "Guidelines for the design and conduct of human clinical trials on ingestion-time differences – chronopharmacology and chronotherapy – of hypertension medications" @default.
- W3115121314 cites W1603364540 @default.
- W3115121314 cites W1714193447 @default.
- W3115121314 cites W1771758286 @default.
- W3115121314 cites W1789433684 @default.
- W3115121314 cites W1967390975 @default.
- W3115121314 cites W1967963000 @default.
- W3115121314 cites W1973686627 @default.
- W3115121314 cites W1981137685 @default.
- W3115121314 cites W1987571194 @default.
- W3115121314 cites W1988440117 @default.
- W3115121314 cites W1990149310 @default.
- W3115121314 cites W1992744537 @default.
- W3115121314 cites W1993590897 @default.
- W3115121314 cites W1996402539 @default.
- W3115121314 cites W1997539987 @default.
- W3115121314 cites W1998619326 @default.
- W3115121314 cites W2001316795 @default.
- W3115121314 cites W2004400528 @default.
- W3115121314 cites W2007298656 @default.
- W3115121314 cites W2009292368 @default.
- W3115121314 cites W2019884347 @default.
- W3115121314 cites W202060702 @default.
- W3115121314 cites W2024731709 @default.
- W3115121314 cites W2031570242 @default.
- W3115121314 cites W2053552427 @default.
- W3115121314 cites W2055421770 @default.
- W3115121314 cites W2056904358 @default.
- W3115121314 cites W2067267160 @default.
- W3115121314 cites W2072841999 @default.
- W3115121314 cites W2073338335 @default.
- W3115121314 cites W2073453419 @default.
- W3115121314 cites W2077723404 @default.
- W3115121314 cites W2077848755 @default.
- W3115121314 cites W2080632719 @default.
- W3115121314 cites W2086941575 @default.
- W3115121314 cites W2088993478 @default.
- W3115121314 cites W2089170650 @default.
- W3115121314 cites W2090472098 @default.
- W3115121314 cites W2090795943 @default.
- W3115121314 cites W2099301718 @default.
- W3115121314 cites W2102420476 @default.
- W3115121314 cites W2102794110 @default.
- W3115121314 cites W2105663232 @default.
- W3115121314 cites W2112961620 @default.
- W3115121314 cites W2116627666 @default.
- W3115121314 cites W2118104235 @default.
- W3115121314 cites W2119953883 @default.
- W3115121314 cites W2130584694 @default.
- W3115121314 cites W2132805205 @default.
- W3115121314 cites W2136649420 @default.
- W3115121314 cites W2138934744 @default.
- W3115121314 cites W2141454310 @default.
- W3115121314 cites W2144059033 @default.
- W3115121314 cites W2147650254 @default.
- W3115121314 cites W2147774101 @default.
- W3115121314 cites W2148875180 @default.
- W3115121314 cites W2150607144 @default.
- W3115121314 cites W2152475612 @default.
- W3115121314 cites W2153553951 @default.
- W3115121314 cites W2158963137 @default.
- W3115121314 cites W2158994710 @default.
- W3115121314 cites W2160368930 @default.
- W3115121314 cites W2162488275 @default.
- W3115121314 cites W2164408451 @default.
- W3115121314 cites W2164771986 @default.
- W3115121314 cites W2167009455 @default.
- W3115121314 cites W2167915551 @default.
- W3115121314 cites W2171931117 @default.
- W3115121314 cites W2174340960 @default.
- W3115121314 cites W2178272175 @default.
- W3115121314 cites W2179628723 @default.